<DOC>
	<DOC>NCT02092896</DOC>
	<brief_summary>The purpose of this study is to: Part 1: To investigate how 12 weeks treatment with liraglutide affects glycemic control in poorly controlled patients and how the treatment affects gastric emptying rate during hypoglycemia. Part 2: To investigate how 12 weeks treatment of type 1 diabetic patients with liraglutide affects counterregulatory hormones and cognitive performance during hypoglycemia.</brief_summary>
	<brief_title>Liraglutide as add-on to Insulin in Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Age: 1870 years BMI: 1828 HbA1c ≥ 8 % No residual βcell function (glucagon test with cpeptide &lt; 60 pM) Caucasian Diagnosed with type 1 diabetes at 5 to 40 years of age (both inclusive). Remission phase must be completed Female participants must use adequate contraception Informed consent Overt diabetes complications; creatinin &gt; 130 µM, proliferative retinopathy, macroalbuminuria. Autonomic neuropathy (RRvariation &lt;/=10 beats/min) and/or Orthostatic hypotension (OH). Anemia, Hb concentration; female &lt;7.0 mmol/l, male&lt;8.0 mmol/l Pregnancy or lactation Epilepsy Use of antiepileptic medication Use of beta blockers Previously apoplexy cerebri. Any use of benzodiazepine within the last month Any use of neuroleptic drugs within the last six months Selfperceived hearing loss Alcohol or drug abuse Allergy to the medication or placebo. Treatment with any medication affecting glucose metabolism. Any disorder which in the investigators opinion could interfere with the safety and results of the trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Diabetes Mellitus, Type 1</keyword>
	<keyword>Glucose Metabolism Disorders</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Cognitive performance</keyword>
	<keyword>Hypoglycemia</keyword>
	<keyword>Insulin</keyword>
	<keyword>Glucagon-Like Peptide 1</keyword>
	<keyword>Hypoglycemic Agents</keyword>
	<keyword>Physiological Effects of Drugs</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Incretins</keyword>
	<keyword>Hormones</keyword>
</DOC>